Provided by Tiger Trade Technology Pte. Ltd.

Cyclerion Therapeutics, Inc.

1.35
+0.04003.05%
Volume:71.97K
Turnover:97.71K
Market Cap:5.30M
PE:-1.76
High:1.39
Open:1.29
Low:1.28
Close:1.31
52wk High:3.79
52wk Low:1.03
Shares:3.93M
Float Shares:3.19M
Volume Ratio:3.27
T/O Rate:2.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7679
EPS(LYR):-1.2141
ROE:-24.80%
ROA:-23.51%
PB:0.56
PE(LYR):-1.11

Loading ...

Cyclerion Therapeutics Inc expected to post a loss of 38 cents a share - Earnings Preview

Reuters
·
Feb 28

BRIEF-Cyclerion Therapeutics Announces Progress Toward Cyc-126 Phase 2 Proof-Of-Concept Study With FDA Feedback

Reuters
·
Feb 17

Cyclerion Therapeutics to Begin Phase 2 CYC-126 Study in Treatment-Resistant Depression in 2026

Reuters
·
Feb 17

Cyclerion Therapeutics Announces Progress Toward Cyc-126 Phase 2 Proof-of-Concept Study With FDA Feedback and Formation of Clinical Advisory Board

THOMSON REUTERS
·
Feb 17

Cyclerion Therapeutics Inc - on Track to Initiate Phase 2 Study in 2026

THOMSON REUTERS
·
Feb 17

Why Cyclerion Therapeutics Shares Are Trading Higher By 44%; Here Are 20 Stocks Moving Premarket

Benzinga_recent_news
·
Jan 06

BRIEF-Cyclerion Announces Strategic Agreement with Medsteer

Reuters
·
Jan 06

Cyclerion Therapeutics Partners with Medsteer to Advance Closed-Loop Anesthetic Platform

Reuters
·
Jan 06

Top Premarket Decliners

MT Newswires Live
·
Sep 25, 2025

BUZZ-Cyclerion Therapeutics jumps on MIT deal to develop depression drug

Reuters
·
Sep 24, 2025

Stocks to Watch: Aytu BioPharma, Cohu, Cyclerion

Dow Jones
·
Sep 24, 2025

BRIEF-Cyclerion Announces Transformational Relaunch As A Neuropsychiatric Company

Reuters
·
Sep 24, 2025

Cyclerion Therapeutics Enters License Agreement With MIT to Relaunch as Neuropsychiatric Firm

MT Newswires Live
·
Sep 24, 2025

Cyclerion Therapeutics - Under License Agreement, Mit Eligible for up to $4.4 Mln in Milestone Payments - SEC Filing

THOMSON REUTERS
·
Sep 24, 2025

Cyclerion enters licensing agreement with MIT, announces strategic relaunch

TIPRANKS
·
Sep 24, 2025

Cyclerion Therapeutics Inc - Phase 2 Trial for Cyclerion's Lead Program Expected in 2026

THOMSON REUTERS
·
Sep 24, 2025

Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company

THOMSON REUTERS
·
Sep 24, 2025